Special assignment on the External Network Transformation team responsible for establishing the strategic direction of the External Development and Manufacturing Network required to support and anticipate the needs of Biogen across all modalities and phases of development.

At Pathways Pharma Consulting (PPC), we offer end-to-end solutions supporting CMC development, manufacturing, program management, and supply chain activities for multiple modalities and assets ranging from preclinical through commercial stages. We are also uniquely positioned to deliver a one-stop-shop contracting process to advance your outsourcing and partnering needs, with leaders in both the business and legal fields on the PPC team.

Responsible for establishing and managing the external manufacturing strategy, operations, and supply network for a pipeline of non-viral gene therapy assets.

Head of External Manufacturing and Supply.CMC Lead for SGT-003, a next generation AAV gene therapy candidate that utilizes a novel muscle-tropic AAV capsid (AAV-SLB101) to deliver Solid’s proprietary and differentiated nNOS microdystrophin for the treatment of Duchenne.Solid Biosciences merged with AavantiBio in December 2022.

Responsible for developing holistic CMC strategy to support Translate Bio's portfolio of assets. Led Buy vs Build strategic assessment that included CDMO landscape evaluation for end-to-end supply (plasmids, enzymes, NTPs, lipids, mRNA, etc.), real estate considerations (greenfield vs brownfield), resource planning, and data digitalization efforts.Translate Bio was acquired by Sanofi in September 2021.

CMC Lead for MRT5005 and Next Generation CF programs. Responsible for developing end-to-end manufacturing strategy to support both mRNA therapeutic and vaccine assets.

Responsible for leading external manufacturing strategy and activities for gene therapy and small molecule clinical assets.

Responsible for managing small molecule and biologics drug substance outsourcing and manufacturing activities supporting preclinical through commercial programs. Led a cross-functional team through a successful process validation of drug substance for LYBALVI™ (ALKS 3831) and established the Alkermes external manufacturing network and strategy to support small molecule clinical assets.

Formerly NuLabel Technologies, Inc.Managed all scale-up operations and outsourcing activities of novel polymeric formulations for application in the adhesives industry.

As process chemist, responsible for development of robust chemical processes that contributed to successful validation of two API. Built a strong foundation in chemical development and manufacturing operations while also gaining valuable experience in CDMO management and CMC strategy.

Research and thesis focused on synthesizing novel I(III) salts and investigating the regiospecificity of their reductive elimination reactions.

Supported research projects focused on quantifying the presence of inflammatory cells in gingiva and the oral mucosa.